Initial Management of Newly Diagnosed Rheumatoid Arthritis

Primary Treatment Strategy

The European League Against Rheumatism (EULAR) recommends methotrexate (MTX) as the anchor drug in rheumatoid arthritis, escalated to approximately 0.3 mg/kg weekly within 4-6 weeks 1
MTX should be started at 15 mg/week and escalated rapidly by 5 mg/month to 25-30 mg/week, as this dosing strategy achieves higher efficacy despite increased toxicity that can be mitigated with folic acid supplementation 2
Oral administration is preferred initially, with a switch to subcutaneous route if insufficient response occurs at the highest tolerable oral dose 3, 2

The American College of Rheumatology and EULAR recommend short-term glucocorticoids as bridging therapy when initiating conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but must be tapered rapidly—typically within 3 months and only exceptionally by 6 months 4, 5
Long-term glucocorticoid use, especially above 5 mg/day prednisone equivalent, should be avoided due to risks including increased cardiovascular mortality at doses above 7.5 mg/day 5

Initiate MTX 15 mg/week orally with folic acid supplementation and add short-term oral prednisone 7.5-10 mg daily as bridging therapy, with goal of discontinuing glucocorticoids by 3 months 1, 3, 5
Escalate MTX by 5 mg/month toward target of 25 mg/week and continue glucocorticoid taper 2, 4
Assess disease activity using composite measures and target significant improvement within 3 months, remission or low disease activity within 6 months 4

No biologic DMARD plus MTX has shown superiority compared with MTX plus glucocorticoids in MTX-naive patients, reinforcing that the DMARD component is essential 1
EULAR 2019 recommendations explicitly state that disease-modifying therapy should start with csDMARDs, ideally combined with glucocorticoids, and strongly discourage initiating therapy with biologics or glucocorticoids alone 1